BHRT (bioheart) seems to be selling the same, or a very similar, machine as cytori. i.e. take adipose tissue and deliver stem cells in 1 hour. Is the design of the device so simple that it will be easily varied sufficiently to bypass patent protection, and so there will be lots of competitors crawling out, or is CYTX not enforcing its patents?
The device you are referring to is the TGI 1200 from a tiny outfit from Hawaii, who sold the rights to develop the therapies based on extraction from adipose tissue of "endothelial cells" to BioHeart. The technology is based on extremely old Williams patents.
In my mind there are very few endothelial cells in adipose tissue, but nonetheless, they are continuing development, which I have also put forward to Cytori more than 2 years ago.
Apparently they are taking a wait and see approach- expecting natural "extinction"- but you might want to ask IR again what the status to date is.
In my mind CYTX is protected in an excellent way by the latest issued patents on Celution and the applications either patented or in process of application for patent.
BHRT...when they came public I recommended them as a short on this board. If you look at the company, they need life support themselves. BHRT does NOT use adipose derived stem cells, rather BHRT uses muscle derived stem cells. CYTX has strong patent protection for its machine and has been adding patents on a monthly basis for the machine or indications and processes. This link discusses BHRT's troubles. http://southflorida.bizjournals.com/southflorida/stories/2009/02/02/daily60.html?ana=yfcpc
One note for those looking at CYTX...CYTX will likely be raising cash at some point soon as well, however they do have sales and a product on the market.
This is from a recent BHRT press release: "Bioheart Announces Commercial Order for TGI 1200(tm) Adult Stem Cell Isolation System for Use in Chronic Limb Ischemia Patients
SUNRISE, Fla., Jan 14, 2009 (GlobeNewswire via COMTEX News Network) -- Bioheart, Inc. (Nasdaq:BHRT) announced today it has received a purchase order for a TGI 1200 System from Philadelphia BioMed Product Development Centre.*
Bioheart's TGI 1200 System is a fully-automated, point-of-care system that recovers potentially regenerative cells from a patient's own fat in about an hour, with minimal operator intervention. No tissue pre-processing is required. The system, distributed by Bioheart under an exclusive license from Tissue Genesis, Inc., accepts adipose (fat) tissue from the same device used for liposuctioning the tissue from the patient. The compact desktop unit readily fits into any clinical environment and uses preconfigured disposables for quick and easy assembly."